Tani Hideki, Shuzo Urata
Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN).
Uirusu. 2018;68(1):51-62. doi: 10.2222/jsv.68.51.
Arenavirus is a genetic term for viruses belonging to the family Arenaviridae and is presented from lymphocytic choriomeningitis virus (LCMV), which shows almost no pathogenicity to humans, to Lassa virus, Junin virus, Machupo virus, Chapare virus, Lujo virus, Sabia virus, and Guanarito virus, which shows high pathogenicity to humans. These viruses except for LCMV are risk group 4 pathogens specified by World Health Organization. Based on this designation, it is designated as Class I pathogens in Japan. Although there have been no reports excluding one imported case of the Lassa fever patient, it is not surprising whenever imported cases occur in our country. Considering the disease severity and mortality rate, it is an urgent matter to develop vaccines and therapeutic drugs in endemic areas, and maintenances of these are also important in countries other than endemic areas. However, basic research on highly pathogenic arenavirus infections and development of therapeutic drugs are not easily progressed, because handling in highly safe research facilities is indispensable. In this article, we will outline the current knowledge from the recent basic research on arenavirus to the development situation of antivirals against arenaviruses.
沙粒病毒是一个遗传学术语,用于指属于沙粒病毒科的病毒,涵盖从对人类几乎无致病性的淋巴细胞性脉络丛脑膜炎病毒(LCMV)到对人类具有高致病性的拉沙病毒、胡宁病毒、马丘波病毒、查帕雷病毒、卢乔病毒、萨比亚病毒和瓜纳里托病毒。除LCMV外,这些病毒均为世界卫生组织指定的危险等级4病原体。据此,在日本被指定为一类病原体。尽管除了1例输入性拉沙热患者外尚无其他报告,但我国出现输入性病例也不足为奇。考虑到疾病的严重程度和死亡率,在流行地区开发疫苗和治疗药物是当务之急,在非流行地区维持这些措施也很重要。然而,由于必须在高度安全的研究设施中进行操作,高致病性沙粒病毒感染的基础研究和治疗药物的开发进展并不容易。在本文中,我们将概述从沙粒病毒的最新基础研究到抗沙粒病毒药物的开发情况的当前知识。